Commercialization Lead Party Sample Clauses

Commercialization Lead Party. Subject to the terms and conditions of this Jounce Lead Co-Co Agreement, Celgene will have sole responsibility, and shall be the Commercialization Lead Party for all Commercialization Activities for Co-Co Products for ROW Administration. Subject to the terms and conditions of this Jounce Lead Co-Co Agreement, including Celgene’s rights under Section 3.1.2, Jounce shall have sole responsibility, and shall be the Commercialization Lead Party for all Co-Co Products for U.S. Administration. Subject to the terms and conditions of this Jounce Lead Co-Co Agreement, including this Article 3, the Commercialization Lead Party for Co-Co Products under this Jounce Lead Co-Co Agreement shall have final decision-making authority with respect to all matters that relate to Commercialization of Co-Co Products solely in the territory for which it serves as the Commercialization Lead Party, in accordance with Section 4.2.5 of the Master Collaboration Agreement. The non-Commercialization Lead Party (itself or by or through any others, including any Affiliates or Sublicensees), will not take any action regarding the Commercialization of Co-Co Products in the countries for which it is not the Jounce Co-Co Lead Party unless (i) described in the U.S. Commercialization Plan or (ii) otherwise approved by the JCC. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
AutoNDA by SimpleDocs
Commercialization Lead Party. Subject to the terms and conditions of this Juno Lead Co-Co Agreement, including Juno’s rights under Section 3.1.3, Celgene will have sole responsibility, and shall be the Commercialization Lead Party for all Commercialization Activities for Juno Program Co-Co Products for Celgene Territory Administration. Subject to the terms and conditions of this Juno Lead Co-Co Agreement, including Celgene’s rights under Section 3.1.2, Juno shall have sole responsibility, and shall be the Commercialization Lead Party for all Juno Program Co-Co Products for Juno Territory Administration, and for clarity Juno retains the sole right to conduct all Commercialization Activities for Juno Program Co-Co Products that are [***] Products in the China Territory as provided in Section 2.1.5 of the Master Collaboration Agreement. Subject to the terms and conditions of this Juno Lead Co-Co [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Agreement, including this Article 3, the Commercialization Lead Party for Juno Program Co-Co Products under this Juno Lead Co-Co Agreement shall [***] Commercialization of Juno Program Co-Co Products [***] as the Commercialization Lead Party, in accordance with Section 4.2.5 of the Master Collaboration Agreement. The non-Commercialization Lead Party (itself or by or through any others, including any Affiliates or Sublicensees, [***] regarding the Commercialization of Juno Program Co-Co Products [***] unless mutually agreed in writing following Celgene’s election to participate in Commercialization Activities pursuant to Section 3.1.2, or Juno’s exercise of the Commercialization Opt-In Right pursuant to Section 3.1.3 (solely in relation to the Major EU Market Countries), or described in the Juno Co-Co Commercialization Plan, or otherwise approved by the JCC.
Commercialization Lead Party. Subject to the terms and conditions of this Celgene Lead Co-Co Agreement, including Juno’s rights under Sections 3.1.2 and 3.1.3, Celgene shall be the Commercialization Lead Party relating to all Celgene Program Co-Co Products for NA Territory Administration and ROW Territory Administration, and [***] with respect to all matters that relate to Commercialization of Celgene Program Co-Co Products throughout the North America Territory and the ROW Territory, after the matter [***]. Juno (itself or by or through any others, including any Affiliates or Sublicensees) will not take any action regarding the Commercialization of Celgene Program Co-Co Products in the Territory unless mutually agreed in writing following Juno’s election to participate in Commercialization Activities pursuant to Sections 3.1.2 or 3.1.3, or described in the Celgene Co-Co Commercialization Plan, or otherwise approved by the JCC.

Related to Commercialization Lead Party

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

Time is Money Join Law Insider Premium to draft better contracts faster.